Previous 10 | Next 10 |
– Overview of its investigational pipeline, planned scientific focus, and future growth drivers – – Wednesday, November 9 th @ 10amET – ANN ARBOR, Mich., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today...
ANN ARBOR, Mich., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2022 financial results before the open of the U.S. financial markets on Tuesday, November 1 st , 2022. Following the release, company management will host a web...
ANN ARBOR, Mich., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that President and CEO, Sheldon Koenig, will present at Morgan Stanley’s 20 th Annual Global Healthcare Conference and also participate in H.C. Wainwright’s Annual Global Investment...
Esperion Therapeutics reported its Q2 earnings that revealed a beat on revenue, but a miss on EPS. However, the company announced that it has hit 100% MACE-4 accumulation. The company’s mixed earnings were only a slight improvement over Q1. I was expecting the market to punish ...
Following earning-led gains in the previous session, Esperion Therapeutics ( NASDAQ: ESPR ), a pharma company focused on high cholesterol levels, dropped Wednesday after Credit Suisse downgraded the stock to Underperform from Neutral, noting a limited upside until a key data r...
Image source: The Motley Fool. Esperion Therapeutics (NASDAQ: ESPR) Q2 2022 Earnings Call Aug 02, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Esperion Therapeutics (ESPR) Q2 2022 Earnings Call Transcript
Start Time: 08:00 End Time: 08:44 Esperion Therapeutics, Inc. (ESPR) Q2 2022 Earnings Conference Call August 02, 2022, 08:00 AM ET Company Participants Sheldon Koenig - President and CEO JoAnne Foody - CMO Eric Warren - Chief Commercial Officer BJ Swa...
Esperion Therapeutics ( NASDAQ: ESPR ) stock rose ~6% on Aug. 2 after Q2 revenue beat analysts' estimates. U.S. net product revenue of cholesterol lowering therapies Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid and ezetimibe) tablets g...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Esperion Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Esperion Therapeutics press release ( NASDAQ: ESPR ): Q2 GAAP EPS of -$1.05 misses by $0.13 . Revenue of $18.84M (-53.7% Y/Y) beats by $0.22M . The decrease is due to a one-time milestone payment from our collaboration partners in the second quarter of 2021, pa...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial ...
U.S. stock futures were mixed this morning, with the Dow futures gaining over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ: ...
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...